摘要
目的观察和比较腹腔热灌注化疗联合静脉化疗与单纯静脉化疗对进展期大肠癌术后腹腔局部复发、肝转移率及3年生存率的影响和不良反应。方法将90例大肠癌根治术后的进展期结直肠癌患者随机分成腹腔热灌注化疗联合静脉化疗组(治疗组)和静脉化疗组(对照组),比较其疗效和生存率。结果治疗组3年腹腔局部复发率、肝转移率及3年生存率分别为15.6%、8.9%、82.2%,而对照组为37.8%、26.7%、62.2%,差异均有统计学意义(P<0.05),两组不良反应差异无统计学意义(P>0.05)。结论影响进展期大肠癌术后生存率的主要原因是癌细胞的肝转移和腹腔局部复发,而腹腔热灌注化疗联合静脉化疗是预防进展期大肠癌术后肝转移和腹腔局部复发非常有效的方法。
Objective To compare the differences in abdominal cavity recurrence rate, hepatic metastasis rate, 3- year survival rate and adverse effect of advanced eolorectal cancer patients treated with chemotherapeutic hyperthermic intraperitoneal perfusion （CHIP） combined with vein chemotherapy （VC） and VC alone after surgery. Methods Ninety advanced colorectal cancer patients treated with radical operation were randomly enrolled. Among them ,45 received CHIP ＋ VC regimen as treatment group, the others received VC regimen only and served as control group. Results In treatment group,3-year abdominal cavity recurrence rate, hepatic metastasis rate and 3-year survival rate were 15.6% , 8.9% , 82. 2% ,which in control group were 37.8%, 26.7%, 62.2% , respectively. The differences bad statistical significance （ P 〈 0. 05 ）. There was no statistical significance in adverse effects between two groups （ P 〉 0.05 ）. Conclusion Hepatic metastasis and abdominal cavity recurrence are the main factors that decrease the survival rate of eolorectal cancer patients after radical operations. CHIP combined with VC regimen is an effective means to prevent it.
出处
《实用肿瘤杂志》
CAS
2014年第1期52-54,共3页
Journal of Practical Oncology
关键词
结直肠肿瘤
药物疗法
药物疗法
联合
输注
胃肠外
高温
诱发
肿瘤转移
复发
colorectal neoplasms
drug therapy
drug therapy, combination
infusion, parenteral
hyperthermia, induced
neoplasm metastasis
recurrence
